These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6660926)

  • 1. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients.
    Nevinny-Stickel J
    Arch Gynecol; 1983; 234(1):27-31. PubMed ID: 6660926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women.
    Kicovic PM; Cortés-Prieto J; Luisi M; Milojevic S; Franchi F
    Reproduccion; 1982; 6(2):81-91. PubMed ID: 6754512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Org OD 14 in the treatment of climacteric complaints.
    Trévoux R; Dieulangard P; Blum A
    Maturitas; 1983 Aug; 5(2):89-96. PubMed ID: 6633272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women.
    Benedek-Jaszmann LJ
    Maturitas; 1987; Suppl 1():25-33. PubMed ID: 3306289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Org OD 14 for the treatment of climacteric complaints.
    De Aloysio D; Fabiani AG; Mauloni M; Bottiglioni F
    Maturitas; 1987; Suppl 1():49-65. PubMed ID: 3306291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo.
    Crona N; Samsioe G; Lindberg UB; Silfverstolpe G
    Maturitas; 1988 Mar; 9(4):303-8. PubMed ID: 3288845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of a new steroid (Org OD 14) in the climacteric syndrome].
    Cittadini J; Ben J; Badano AR; Denari HJ; Quiroga S; Marcus AE; Schlaen I; Figueroa Casas PR
    Reproduccion; 1982; 6(2):69-79. PubMed ID: 6814971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis.
    Lindsay R; Hart DM; Kraszewski A
    Br Med J; 1980 May; 280(6225):1207-9. PubMed ID: 6992927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14.
    Cortes-Prieto J
    Maturitas; 1987; Suppl 1():67-72. PubMed ID: 3306292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of different hormonal replacement therapies in post-menopausal women.
    Volpe A; Facchinetti F; Grasso A; Petraglia F; Campanini D; Genazzani AR
    Maturitas; 1986 Dec; 8(4):327-34. PubMed ID: 3033444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New steroid for the climacteric syndrome.
    Kicovic PM
    Minerva Endocrinol; 1989; 14(1):63-7. PubMed ID: 2659954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day.
    Landgren MB; Helmond FA; Engelen S
    Maturitas; 2005 Mar; 50(3):222-30. PubMed ID: 15734603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of tibolone and estrogen replacement therapy on echocardiographic basic cardiac functions in post-menopausal women: a randomized placebo controlled study.
    Taskin O; Muderrisoglu H; Akar M; Simsek M; Mendilcioglu I; Kursun S
    Maturitas; 2004 Aug; 48(4):354-9. PubMed ID: 15283927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
    Hudita D; Posea C; Ceausu I; Rusu M
    Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response analysis of effects of tibolone on climacteric symptoms.
    Landgren MB; Bennink HJ; Helmond FA; Engelen S
    BJOG; 2002 Oct; 109(10):1109-14. PubMed ID: 12387462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soy germ extract alleviates menopausal hot flushes: placebo-controlled double-blind trial.
    Imhof M; Gocan A; Imhof M; Schmidt M
    Eur J Clin Nutr; 2018 Jul; 72(7):961-970. PubMed ID: 29849181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women.
    Saure A; Planellas J; Poulsen HK; Jaszczak P
    Maturitas; 2000 Feb; 34(2):133-42. PubMed ID: 10714908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis.
    Geusens P; Dequeker J; Gielen J; Schot LP
    Maturitas; 1991 Jun; 13(2):155-62. PubMed ID: 1921738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
    Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
    Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.